Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
All studies
Mortality
ICU
Hospitalization
Serious outcomes
Cases
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Bromhexine  COVID-19 treatment studies for Bromhexine  C19 studies: Bromhexine  Bromhexine   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Molnupiravir
Bamlanivimab Nigella Sativa
Bromhexine Nitazoxanide
Budesonide Povidone-Iod..
Casirivimab/i.. Probiotics
Colchicine Proxalutamide
Conv. Plasma Quercetin
Curcumin Remdesivir
Favipiravir Sotrovimab
Fluvoxamine Vitamin A
Hydroxychloro.. Vitamin C
Iota-carragee.. Vitamin D
Ivermectin Zinc
Melatonin

Other Adoption
Outcomes in COVID-19 bromhexine studies
00.250.50.7511.251.51.752+Ansarin (RCT)91%0.09 [0.01-1.59]death0/395/39Improvement, RR [CI]TreatmentControlLi (RCT)75%0.25 [0.06-1.00]no disch.2/124/6Tau​2 = 0.00; I​2 = 0.0%Early treatment79%0.21 [0.06-0.72]2/519/4579% improvementMareev (RCT)39%0.61 [0.14-0.97]no disch.14/2420/21Improvement, RR [CI]TreatmentControlTolouian (RCT)76%0.24 [0.01-8.03]death48 (n)52 (n)Tau​2 = 0.00; I​2 = 0.0%Late treatment39%0.61 [0.43-0.86]14/7220/7339% improvementMikhaylov (RCT)80%0.20 [0.01-3.97]hosp.0/252/25Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP80%0.20 [0.01-3.97]0/252/2580% improvementAll studies45%0.55 [0.40-0.77]16/14831/14345% improvement5 bromhexine COVID-19 studiesc19bromhexine.com Sep 25, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 3.46Effect extraction pre-specifiedFavors bromhexineFavors control 00.250.50.7511.251.51.752+Ansarin (RCT)91%0.09 [0.01-1.59]0/395/39Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment91%0.09 [0.01-1.59]0/395/3991% improvementTolouian (RCT)76%0.24 [0.01-8.03]48 (n)52 (n)Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment76%0.24 [0.01-8.03]0/480/5276% improvementAll studies87%0.13 [0.01-1.23]0/875/9187% improvement2 bromhexine COVID-19 mortality resultsc19bromhexine.com Sep 25, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 1.78Favors bromhexineFavors control 00.250.50.7511.251.51.752+Ansarin (RCT)82%0.18 [0.04-0.77]2/3911/39Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment82%0.18 [0.04-0.77]2/3911/3982% improvementAll studies82%0.18 [0.04-0.77]2/3911/3982% improvement1 bromhexine COVID-19 ICU resultc19bromhexine.com Sep 25, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 2.32Favors bromhexineFavors control 00.250.50.7511.251.51.752+Mikhaylov (RCT)80%0.20 [0.01-3.97]hosp.0/252/25Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP80%0.20 [0.01-3.97]0/252/2580% improvementAll studies80%0.20 [0.01-3.97]0/252/2580% improvement1 bromhexine COVID-19 hospitalization resultc19bromhexine.com Sep 25, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 1.06Favors bromhexineFavors control 00.250.50.7511.251.51.752+Ansarin (RCT)91%0.09 [0.01-1.59]death0/395/39Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment91%0.09 [0.01-1.59]0/395/3991% improvementTolouian (RCT)76%0.24 [0.01-8.03]death48 (n)52 (n)Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment76%0.24 [0.01-8.03]0/480/5276% improvementMikhaylov (RCT)80%0.20 [0.01-3.97]hosp.0/252/25Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP80%0.20 [0.01-3.97]0/252/2580% improvementAll studies85%0.15 [0.03-0.92]0/1127/11685% improvement3 bromhexine COVID-19 serious outcomesc19bromhexine.com Sep 25, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 2.06Effect extraction pre-specifiedFavors bromhexineFavors control 00.250.50.7511.251.51.752+Tolouian (RCT)-75%1.75 [1.13-2.71]29/4818/52Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment-75%1.75 [1.13-2.71]29/4818/52-75% improvementAll studies-75%1.75 [1.13-2.71]29/4818/52-75% improvement1 bromhexine COVID-19 case resultc19bromhexine.com Sep 25, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 2.49Favors bromhexineFavors control 00.250.50.7511.251.51.752+Mareev (RCT)87%0.13 [0.01-2.25]viral+0/173/13Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment87%0.13 [0.01-2.25]0/173/1387% improvementMikhaylov (RCT)71%0.29 [0.07-1.24]viral+2/257/25Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP71%0.29 [0.07-1.24]2/257/2571% improvementAll studies76%0.24 [0.07-0.89]2/4210/3876% improvement2 bromhexine COVID-19 viral clearance resultsc19bromhexine.com Sep 25, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 2.13Favors bromhexineFavors control 00.250.50.7511.251.51.752+Ansarin (RCT)91%0.09 [0.01-1.59]death0/395/39Improvement, RR [CI]TreatmentControlLi (RCT)75%0.25 [0.06-1.00]no disch.2/124/6Tau​2 = 0.00; I​2 = 0.0%Early treatment79%0.21 [0.06-0.72]2/519/4579% improvementMareev (RCT)39%0.61 [0.14-0.97]no disch.14/2420/21Improvement, RR [CI]TreatmentControlTolouian (RCT)76%0.24 [0.01-8.03]death48 (n)52 (n)Tau​2 = 0.00; I​2 = 0.0%Late treatment39%0.61 [0.43-0.86]14/7220/7339% improvementMikhaylov (RCT)80%0.20 [0.01-3.97]hosp.0/252/25Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP80%0.20 [0.01-3.97]0/252/2580% improvementAll studies45%0.55 [0.40-0.77]16/14831/14345% improvement5 bromhexine COVID-19 Randomized Controlled Trialsc19bromhexine.com Sep 25, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 3.46Effect extraction pre-specifiedFavors bromhexineFavors control 00.250.50.7511.251.51.752+Ansarin (RCT)91%0.09 [0.01-1.59]0/395/39Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment91%0.09 [0.01-1.59]0/395/3991% improvementTolouian (RCT)76%0.24 [0.01-8.03]48 (n)52 (n)Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment76%0.24 [0.01-8.03]0/480/5276% improvementAll studies87%0.13 [0.01-1.23]0/875/9187% improvement2 bromhexine COVID-19 RCT mortality resultsc19bromhexine.com Sep 25, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 1.78Favors bromhexineFavors control 00.250.50.7511.251.51.752+Ansarin (RCT)91%0.09 [0.01-1.59]death0/395/39Improvement, RR [CI]TreatmentControlLi (RCT)75%0.25 [0.06-1.00]no disch.2/124/6Tau​2 = 0.00; I​2 = 0.0%Early treatment79%0.21 [0.06-0.72]2/519/4579% improvementMareev (RCT)39%0.61 [0.14-0.97]no disch.14/2420/21Improvement, RR [CI]TreatmentControlTolouian (RCT)76%0.24 [0.01-8.03]death48 (n)52 (n)Tau​2 = 0.00; I​2 = 0.0%Late treatment39%0.61 [0.43-0.86]14/7220/7339% improvementAll studies50%0.50 [0.29-0.85]16/12329/11850% improvement4 bromhexine COVID-19 peer reviewed trialsc19bromhexine.com Sep 25, 2021Tau​2 = 0.06; I​2 = 9.9%; Z = 2.53Effect extraction pre-specifiedFavors bromhexineFavors control 00.250.50.7511.251.51.752+Ansarin (RCT)91%0.09 [0.01-1.59]death0/395/39Improvement, RR [CI]TreatmentControlAnsarin (RCT)89%0.11 [0.01-0.84]ventilation1/399/39Ansarin (RCT)82%0.18 [0.04-0.77]ICU2/3911/39Li (RCT)75%0.25 [0.06-1.00]no disch.2/124/6Li (RCT)50%0.50 [0.09-2.73]oxygen2/122/6Mareev (RCT)39%0.61 [0.14-0.97]no disch.14/2420/21Mareev (RCT)87%0.13 [0.01-2.25]viral+0/173/13Tolouian (RCT)76%0.24 [0.01-8.03]death48 (n)52 (n)Tolouian (RCT)76%0.24 [0.01-7.69]no improv.48 (n)52 (n)Tolouian (RCT)-75%1.75 [1.13-2.71]cases29/4818/52Mikhaylov (RCT)80%0.20 [0.01-3.97]hosp.0/252/25Mikhaylov (RCT)91%0.09 [0.01-1.56]symp. case0/255/25Mikhaylov (RCT)71%0.29 [0.07-1.24]viral+2/257/25bromhexine COVID-19 outcomesc19bromhexine.com Sep 25, 2021Favors bromhexineFavors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit